NEWS DETAIL

A combinação de dabrafenibe e trametinibe como tratamento de segunda linha para pacientes com câncer de pulmão com mutação BRAF V600 alcança uma sobrevida livre de progressão (SLP) de 15 meses! – Sina Finance

转自: 医学界网站BRAF突变患者, 二线接受“D+T”双靶治疗, 安全性良好, 长生存获益。

Informações médicas

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

文章相關商品

系統已根據文章標題、摘要和正文,自動匹配目前在售的強相關藥品。

常見問題

Which products are related to this article?

The system matched these relevant products from the article content: 盧修斯 曲美替尼 Trametinib 線上購買、盧修斯 達拉非尼 Dabrafenib 在線購買、達拉非尼膠囊 DABRADX Dabrafenib 75mg、曲美替尼錠 TRAMEDX Trametinib 2mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp 微信 微信